E7080, known as lenvatinib, is an oral multitargeted tyrosine kinase inhibitor including VEGF, FGF and SCF receptors that has been shown to improve the survival rate of patients with radioiodine-refractory thyroid cancer. Lenvatinib (E7080) had antitumor activity against HCC PDX models, likely through its potent anti-angiogenic activity [1].
Lenvatinib (E7080) inhibited Flt-1, KDR, Flt-4 with IC50 values of 22, 4.0 and 5.2 nM, respectively. Lenvatinib (E7080) inhibited FGFR1 and FDGFR tyrosine kinases. In addition to these kinases, Lenvatinib (E7080) also inhibited KIT kinase with an IC50 value of 100 nM [2]. The half-maximal inhibitory concentrations (IC50 ) for Lenvatinib (E7080) treatment of 8505C and TCO1 cells were 24.26 and 26.32 μM, respectively [3].
The novel multi-targeted kinase inhibitor Lenvatinib (E7080), which inhibited both KDR and KIT kinases, showed a more potent antitumor efficacy against H146 tumor than imatinib. Oral administration of Lenvatinib (E7080) inhibited the growth of H146 tumor at 30 and 100 mg/kg in a dose-dependent manner and caused tumor regression at 100 mg/kg [2]. Lenvatinib (E7080) at 10 and 30 mg/kg inhibited the tumor growth of both PDXs, LI0050 and LI0334 [1]. Lenvatinib (E7080), as compared with placebo, was associated with significant prolongation of progression-free survival and an improved response rate (64.8% vs. 1.5%) among patients with iodine-131–refractory differentiated thyroid cancer [4].
References:
[1].Matsuki M, Hoshi T, Yamamoto Y, Ikemori-Kawada M, Minoshima Y, Funahashi Y, Matsui J. Lenvatinib inhibits angiogenesis and tumor fibroblast growth factor signaling pathways in human hepatocellular carcinoma models. Cancer Med. 2018 Jun;7(6):2641-2653.
[2].Matsui J, Yamamoto Y, Funahashi Y, Tsuruoka A, Watanabe T, Wakabayashi T, Uenaka T, Asada M. E7080, a novel inhibitor that targets multiple kinases, has potent antitumor activities against stem cell factor producing human small cell lung cancer H146, based on angiogenesis inhibition. Int J Cancer. 2008 Feb 1;122(3):664-71.
[3].Enomoto K, Hirayama S, Kumashiro N, Jing X, Kimura T, Tamagawa S, Matsuzaki I, Murata SI, Hotomi M. Synergistic Effects of Lenvatinib (E7080) and MEK Inhibitors against Anaplastic Thyroid Cancer in Preclinical Models. Cancers (Basel). 2021 Feb 18;13(4):862.
[4].Schlumberger M, Tahara M, Wirth LJ, Robinson B, Brose MS, Elisei R, Habra MA, Newbold K, Shah MH, Hoff AO, Gianoukakis AG, Kiyota N, Taylor MH, Kim SB, Krzyzanowska MK, Dutcus CE, de las Heras B, Zhu J, Sherman SI. Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N Engl J Med. 2015 Feb 12;372(7):621-30.
E7080,称为乐伐替尼,是一种口服多靶点酪氨酸激酶抑制剂,包括 VEGF、FGF 和 SCF 受体,已被证明可以提高放射性碘难治性甲状腺癌患者的生存率。 Lenvatinib (E7080) 对 HCC PDX 模型具有抗肿瘤活性,这可能是通过其有效的抗血管生成活性[1]。
Lenvatinib (E7080) 抑制 Flt-1、KDR、Flt-4,IC50 值分别为 22、4.0 和 5.2 nM。 Lenvatinib (E7080) 抑制 FGFR1 和 FDGFR 酪氨酸激酶。除了这些激酶,乐伐替尼 (E7080) 还抑制 KIT 激酶,IC50 值为 100 nM [2]。 Lenvatinib (E7080) 处理 8505C 和 TCO1 细胞的半数最大抑制浓度 (IC50 ) 分别为 24.26 和 26.32 μM [3]。
新型多靶点激酶抑制剂乐伐替尼 (Lenvatinib) (E7080) 可同时抑制 KDR 和 KIT 激酶,对 H146 肿瘤显示出比伊马替尼更有效的抗肿瘤功效。口服乐伐替尼 (E7080) 在 30 和 100 mg/kg 时以剂量依赖性方式抑制 H146 肿瘤的生长,在 100 mg/kg 时引起肿瘤消退 [2]。 10 和 30 mg/kg 的乐伐替尼 (E7080) 抑制了 PDX、LI0050 和 LI0334 的肿瘤生长[1]。与安慰剂相比,乐伐替尼 (E7080) 与碘 131 难治性分化型甲状腺癌患者的无进展生存期显着延长和缓解率提高（64.8% 对 1.5%）相关[4] .